Thymosin Alpha-1 at a Glance

• Thymosin alpha-1 (Tα1) is a 28-amino-acid, N-terminally acetylated peptide generated by proteolytic cleavage of the precursor protein prothymosin alpha. It was originally isolated from thymic tissue, which is the source of its name and of most of its mechanistic framing.
• Its best-characterised activity is innate immune signalling through Toll-like receptors, principally TLR9 and TLR2, on dendritic cells and monocytes producing dendritic cell maturation and a shift toward Th1-polarised responses.
• As the pharmaceutical thymalfasin (trade name Zadaxin), it is a licensed medicine in more than 35 countries for indications including chronic hepatitis B and C. It has never received FDA marketing approval in the United States.
• The respiratory and critical-care evidence is negative where it is strongest. The Chinese ETASS trial in severe sepsis reported a mortality difference that missed conventional significance; the much larger TESTS phase 3 trial, published in The BMJ in 2025, found no benefit on 28-day mortality.
• The COVID-19 literature is large, largely retrospective and methodologically weak with pooled analyses reporting favourable mortality signals under severe heterogeneity. Material sold for laboratory work is research-use-only: an approved product in other jurisdictions confers no status on research-grade peptide, and conflating the two is the most common error in this market.

What Is Thymosin Alpha-1?

Thymosin alpha-1 is a 28-residue polypeptide with an acetylated N-terminal serine catalogued in PubChem as thymalfasin, CID 16130571, with the molecular formula C₁₂₉H₂₁₅N₃₃O₅₅ and a mass of approximately 3,108 Da. At roughly three kilodaltons it sits at the upper end of what is conventionally called a peptide, and its handling behaviour reflects that.

Tα1 was identified within thymosin fraction 5 a partially purified thymic extract prepared in Allan Goldstein’s laboratory, and was the first component of that fraction to be sequenced and synthesised. Its biogenesis is now understood more specifically: Tα1 is produced by asparagine endopeptidase cleavage of prothymosin alpha which is expressed broadly rather than only in thymus. The peptide is therefore not a thymic hormone in the strict endocrine sense, it is a fragment of an abundant nuclear protein that acquires signalling activity when released.

Two structural features matter for reading the literature. The N-terminal acetylation is not decorative: it blocks aminopeptidase attack and is present in the native molecule, so synthetic material lacking it is a different compound with different stability. And the molecule is intrinsically disordered in solution with no stable tertiary fold, engaging multiple targets with low individual affinity rather than one receptor with high affinity, which is why decades of work have not produced a canonical “thymosin alpha-1 receptor.”

How Does Thymosin Alpha-1 Work?

Toll-Like Receptor Signalling and Dendritic Cell Maturation

The most substantial mechanistic finding is that Tα1 acts on innate sensing pathways not directly on T cells as the older thymic-hormone framing implied.

Romani and colleagues (2004, PMID 14982877) reported in Blood that Tα1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signalling in models of Aspergillus fumigatus and Candida albicans infection. The dependence was demonstrated genetically rather than pharmacologically: protection required intact TLR/MyD88 signalling, implicating TLR9 in particular alongside TLR2. A 2007 report (PMID 17804687) extended this to viral sensing, finding that Tα1 activates TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of antiviral responses in vivo, a type I interferon pathway rather than a T-cell pathway.

Beyond dendritic cells, Tα1 has been reported to activate complement receptor-mediated phagocytosis in human monocyte-derived macrophages, and recent in vitro profiling across tumour cell lines and immune cell subsets suggests a peptide with many low-affinity interactions distributed across innate cell types consistent with the disordered structural account, inconsistent with a single-receptor model.

The practical consequence is that the effect is conditional on context. Tα1 does not simply stimulate immunity; it augments a sensing pathway that must already have something to sense. That predicts modest or absent effects in unselected populations, and is a plausible part of why mechanistic models have outperformed clinical trials.

T-Cell Development and the Thymic Origin

The classical account, which remains partly supported, concerns thymopoiesis and T-cell differentiation. Thymic extracts were originally studied because neonatal thymectomy produced profound lymphopenia, and Tα1 was pursued as the active principle restoring T-cell competence. In the modern literature this appears as effects on T-cell maturation markers, CD4/CD8 subset ratios, and IL-2 and interferon-gamma production with an associated shift away from Th2 and toward Th1 phenotypes; a comprehensive review of the literature (PMID 33362999) collects this material across indications.

A more recent theme is regulatory T cells with some work reporting increased Treg frequency or function, the opposite direction to the Th1-augmenting account. The standard reconciliation is that Tα1 acts as an immune modulator whose direction depends on baseline state. That formulation is appealing and also conveniently unfalsifiable, and readers should notice it is used to explain both positive and negative findings.

Antiviral and Interferon-Related Pathways

For respiratory and hepatic work the interferon axis is the mechanistic bridge. A 2023 review in Molecules (PMID 37110771) sets out the proposed chain: TLR-dependent innate activation, induction of type I and type II interferon responses, enhanced antigen presentation, and improved cytotoxic T-lymphocyte priming. It predicts the compound should perform best as an adjunct to something with direct antiviral action rather than as monotherapy.

Research Evidence

In Vitro and Animal Work

The preclinical dataset is unusually coherent for a research peptide of this vintage, because the mechanism was interrogated with receptor- and adaptor-deficient mice rather than only with dose–response curves. Concentrations in cell work are typically nanomolar to low micromolar; animal work is reported in micrograms per kilogram by subcutaneous or intraperitoneal injection, in the terms the cited studies use for the specific model and not as recommendations transferable between species or routes. The main limitation is that the models are acute infection challenges in mice, a poor surrogate for the chronic, heterogeneous conditions in which the compound has been used clinically.

Chronic Hepatitis B and C

This is the indication on which thymalfasin was licensed in most markets, and the evidence is older and more equivocal than the marketing history implies. A meta-analysis comparing thymosin alpha-1 with interferon alpha in chronic hepatitis B (PMID 18078676) is among the more useful summaries; the general finding is a delayed and modest virological effect with response rates emerging after treatment cessation rather than during therapy. In hepatitis C the compound was studied mainly alongside interferon, a question since made largely moot by direct-acting antivirals, important context in itself, since the principal licensed indication was overtaken by a far more effective class.

Sepsis: ETASS and TESTS

For a critical-care readership this is the most instructive sequence in the dossier, because it is a rare case of a research peptide taken all the way to an adequately powered phase 3 trial.

ETASS the efficacy of thymosin alpha 1 for severe sepsis, was a multicentre, single-blind, randomised controlled trial across six tertiary teaching hospitals in China between 2008 and 2010, reported in Critical Care in 2013 (PMID 23327199). It randomised 361 patients to a subcutaneous Tα1 regimen specified in the protocol plus conventional therapy, or conventional therapy alone. All-cause 28-day mortality was 26.0% versus 35.0%. On the pre-specified non-stratified analysis this did not reach conventional significance (P = 0.062), although a log-rank comparison of survival curves did (P = 0.049). The authors concluded the therapy “may be effective in improving clinical outcomes in a targeted population of severe sepsis.” That is a careful, hedged conclusion, and it was widely reported as considerably stronger than it was; the trial was single-blind with no placebo, which in a mortality trial with open-label control is a meaningful limitation.

TESTS was the confirmatory trial. Reported in The BMJ in 2025 (PMID 39814420), it was a multicentre, double-blinded, randomised, placebo-controlled phase 3 trial at 22 Chinese centres, enrolling 1,106 adults with sepsis with 1,089 in the modified intention-to-treat analysis. Twenty-eight-day all-cause mortality was 23.4% with Tα1 versus 24.1% with placebo a hazard ratio of 0.97 (95% CI 0.76–1.24, P = 0.82). The authors reported no clear evidence that thymosin α1 decreases 28-day all-cause mortality in adults with sepsis with no significant differences in secondary or safety outcomes.

The lesson is the standard one. A promising, borderline, single-blind trial was followed by a properly blinded trial three times larger, and the effect disappeared. Subgroup analyses in TESTS suggested possible differential effects by age and diabetes status; those are hypotheses, not findings. Any pooled sepsis estimate predating TESTS is obsolete.

COVID-19 and Respiratory Infection

The COVID-19 era produced a large volume of Tα1 literature very quickly, and its quality is the main thing to understand about it. The bulk consists of retrospective cohorts and propensity-matched analyses from Chinese centres where the compound was already licensed and in routine use, and designs of that kind cannot exclude confounding by indication.

Pooled analyses report favourable signals. A 2023 systematic review, meta-analysis and meta-regression in Inflammopharmacology (PMID 37845598) pooled eight studies in moderate to critical COVID-19 and reported a mortality risk ratio of 0.59 (95% CI 0.37–0.93, P = 0.02) with substantial heterogeneity (I² = 84%) no significant effect on mechanical ventilation or length of stay, and an explicit conclusion that randomised trials are still required. A risk ratio pooled from observational studies with heterogeneity at that level is a hypothesis, not a result.

The older respiratory literature, ventilator-associated pneumonia, exacerbations of chronic obstructive pulmonary disease, has the same structural problem: small studies, frequently unblinded, concentrated in jurisdictions where the drug was already marketed. No adequately powered blinded trial exists for any respiratory indication.

Immune Reconstitution in Oncology and Transplantation

Arguably the most mechanistically appropriate clinical setting is one where immune function is measurably deficient rather than dysregulated. Perruccio and colleagues (2010, PMID 20536464) reported on Tα1 to harness immunity to pathogens after haploidentical haematopoietic transplantation a setting of profound T-cell deficiency in which a thymopoietic agent has a clear rationale, and later work examined immune recovery after stem cell transplantation in multiple myeloma. These studies generally report improvements in immunological surrogates lymphocyte subset recovery, CD4 counts, functional responses, with smaller and less consistent effects on infection-related clinical endpoints.

What Remains Unknown

No high-affinity receptor has been identified. Four decades after sequencing, the mechanism is described in terms of low-affinity engagement of TLRs and other innate receptors by a disordered peptide. Coherent as that is, it makes conventional pharmacology, binding affinity, occupancy, target-defined dose–response, unavailable.

The direction of effect is not predictable in advance. The literature reports both immune augmentation and immune restraint, with no validated biomarker identifying which a given model or patient will show, and without such a marker the modulator framing cannot be tested.

The sepsis question is now largely closed and the respiratory question is not open in a useful way. TESTS was adequately powered and null; the respiratory evidence is observational. A search of ClinicalTrials.gov returns registered studies across several indications, but the field has not produced a second TESTS-scale result.

Comparison: Thymosin Alpha-1, KPV and BPC-157

Laboratories working on immune and mucosal barrier questions frequently hold all three despite their having almost nothing in common mechanistically. The useful axis is what kind of evidence each one actually has.

KPV is the tripeptide Lys-Pro-Val, the C-terminal tripeptide of α-melanocyte-stimulating hormone. Its evidence base is preclinical and mucosal: Dalmasso and colleagues (2008, PMID 18061177) reported in Gastroenterology that PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Catalogues list KPV peptide as a separate research compound, and the contrast with Tα1 is instructive: KPV has a defined transporter-mediated uptake route and a plausible receptor family but essentially no human data, whereas Tα1 has extensive human data and no defined receptor.

BPC-157 is a fifteen-residue peptide corresponding to a partial sequence of a protein isolated from gastric juice, studied mainly in rodent injury models; a 2019 review covers its reported role in accelerating musculoskeletal soft-tissue healing (PMID 30915550). BPC-157 appears in the same catalogues, and its literature is dominated by one research programme with no adequately powered human trial. For a laboratory holding all three, the general point is that these are not members of a class and are not substitutable.

Handling and Reconstitution of Lyophilised Thymosin Alpha-1

At 28 residues and roughly 3.1 kDa, Tα1 is a substantially larger and more delicate molecule than the tripeptides and tetrapeptides common in research catalogues.

Solubility is not the constraint the sequence is acidic and strongly hydrophilic, so the peptide dissolves readily in aqueous buffer without organic co-solvent. Surface adsorption and aggregation are the real constraints. A three-kilodalton disordered peptide at low concentration loses appreciable material to glass and plastic, and the loss is not proportional across concentrations, dilute working solutions suffer most. Low-binding polypropylene, a carrier protein where the assay tolerates one, and avoidance of unnecessary dilution steps matter more here than for a short peptide, and vigorous agitation that drives air–liquid interfacial denaturation is a genuine risk rather than a formality.

The N-terminal acetyl group is the stability keystone. It protects against aminopeptidase cleavage, and the degradation routes that remain are deamidation at asparagine and glutamine and backbone hydrolysis, both accelerated by extremes of pH and temperature.

Practical reconstitution follows the standard sequence: equilibrate the vial to room temperature before opening so moisture does not condense onto the cold cake, disinfect the septum with 70% isopropyl alcohol and let it dry, introduce the diluent slowly down the inner wall of the vial rather than jetting it onto the cake, and swirl or roll gently rather than shaking.

Where a vial will be entered more than once, a preserved monographed diluent is the conventional laboratory choice, and bacteriostatic water listed alongside research compounds at NextGenPeps, or an equivalent Bacteriostatic Water for Injection, USP product, is what most protocols specify. Two caveats belong in the record. Benzyl alcohol is not inert toward peptides the formulation literature documents preservative-promoted unfolding and aggregation across multiple model peptides, and for a disordered three-kilodalton molecule that concern is more than theoretical, so single-entry analytical preparations are better served by unpreserved sterile water. And it is contraindicated in neonatal use because of benzyl alcohol toxicity, a restriction that belongs in handling documentation even where no clinical use is contemplated.

Store reconstituted solution at 2–8 °C, aliquot at the point of reconstitution rather than freeze–thawing repeatedly, and log the diluent lot alongside the peptide lot.

Is Thymosin Alpha-1 FDA Approved?

No. Thymosin alpha-1 has never received FDA marketing approval in the United States, for any indication. This is the point on which public information about the compound is most often wrong, and the confusion is worth unpicking precisely.

Thymalfasin marketed as Zadaxin is a licensed pharmaceutical in more than 35 countries with indications that variously include chronic hepatitis B and C, malignant melanoma as an adjunct, and use in immunodeficiency and respiratory infection depending on jurisdiction. Its US regulatory history is different: it has held orphan drug designations from the FDA for indications including malignant melanoma and hepatocellular carcinoma. Orphan designation is not approval it is a development incentive granted on the basis of indication rarity, awarded before efficacy is established, and confers no permission to market. Some published reviews describe Zadaxin loosely as an FDA-approved thymosin product; that description does not survive contact with the FDA’s own approved-drug records.

Thymosin alpha-1 is likewise not a lawful dietary supplement ingredient in the United States. A 28-residue synthetic peptide does not qualify as a dietary ingredient, and marketing it for human consumption places it outside both the drug and supplement frameworks.

One further part of the record is often misrepresented. The FDA maintains a list of certain bulk drug substances for use in compounding that may present significant safety risks, and thymosin alpha-1 appears in the record of that process as a withdrawn nomination rather than as a substance on the active list. Neither inclusion on nor absence from that list constitutes approval, and the list governs pharmacy compounding, not research use.

The practical consequence is the ordinary one: material purchased for research is research-use-only no regulatory body has assessed the identity, purity or safety of any research-grade lot, and supplier documentation carries the entire evidentiary burden.

Where to Buy Research-Grade Thymosin Alpha-1

Sourcing is genuinely harder for this compound than for a short peptide. A 28-mer is long enough that synthesis failures are common, and several of the most likely impurities are difficult to detect without properly resolved analysis.

What the Analytical Package Should Contain

• A lot-matched certificate of analysis tied to the specific lot shipped rather than to a representative or historical batch. A COA for “a recent production run” is not a COA for what arrived.
• Third-party HPLC purity data with a named laboratory, a stated method and a test date. The realistic impurities in a 28-residue synthesis are deletion sequences from incomplete coupling, truncated fragments and deamidated species. Deletion of one small residue changes mass by well under one percent and can co-elute with product on a coarse gradient, so a flat, unresolved chromatogram is uninformative even when it looks clean.
• Mass spectrometry confirming identity with an observed mass consistent with the expected ~3,108 Da. Here the MS record does a job beyond identity: it is the practical check that the N-terminal acetyl group is present since the des-acetyl peptide differs by 42 Da. A supplier that cannot evidence acetylation is not evidencing thymosin alpha-1.
• Declared net peptide content distinct from gross vial fill weight, plus residual trifluoroacetate data where available, TFA contributes mass and is cytotoxic at low concentrations in culture.
• Endotoxin data where the intended use is cell-based immunology. The proposed mechanism runs through TLR2 and TLR9 and bacterial endotoxin is a TLR4 agonist producing overlapping readouts, so a contaminated preparation can generate exactly the result the experiment is looking for by the wrong pathway.
• Cold-chain shipping and explicit research-use-only labelling with no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red Flags in Listings and Documentation

• Any listing that describes the compound as FDA approved. This is the most common and most diagnostic error in this market. It indicates the page was written without checking the primary regulatory record, and raises a reasonable question about what else was not checked.
• Presenting the ETASS sepsis result as established efficacy without reference to TESTS. A page still citing the 2013 borderline result as proof the compound works in sepsis is either unaware of a major 2025 BMJ publication or has chosen not to mention it.
• Citing pooled COVID-19 mortality estimates as clinical proof. The authors of those analyses say plainly that randomised confirmation is required.
• Purity claims of “99%+” with no chromatogram, named method or test date or a COA with no named laboratory and no lot reference. Documentation of that kind is decoration.
• Any protocol content, reconstitution guidance framed for a person, or “research participant” language a compliance signal about the supplier, independent of product quality.
• A price substantially below market for a 28-residue peptide. Long peptides are expensive to make well.

A catalogue that lists thymosin alpha 1 as a research compound can be assessed against exactly those criteria, in that order: lot-matched third-party HPLC with a resolved chromatogram; mass spectrometry consistent with the acetylated 28-mer; declared net peptide content; residual TFA and endotoxin figures where the work requires them; documented cold chain; and research-use-only labelling with no protocol content attached. The same checklist applies to any supplier.

Frequently Asked Questions

Is thymosin alpha-1 the same thing as thymalfasin or Zadaxin?

Chemically, yes. Thymalfasin is the international non-proprietary name for synthetic thymosin alpha-1, and Zadaxin is a trade name for a thymalfasin product. Legally they are not interchangeable: Zadaxin is a licensed pharmaceutical released under pharmaceutical quality systems where it is approved, while research-grade thymosin alpha-1 is an unapproved chemical sold for laboratory use with no regulatory assessment of any kind.

Does thymosin alpha-1 work in sepsis?

The best available evidence says no. The 2013 ETASS trial in 361 patients reported 28-day mortality of 26.0% versus 35.0%, which did not reach conventional significance on its primary analysis. The much larger, properly blinded TESTS phase 3 trial, published in The BMJ in 2025 with 1,106 participants, reported 23.4% versus 24.1% and a hazard ratio of 0.97. Meta-analyses published before TESTS should be considered superseded.

How strong is the COVID-19 evidence?

Weak. Most of it is retrospective and propensity-matched from centres where the compound was already in routine use, which cannot exclude confounding by indication. A 2023 meta-analysis pooled eight studies and reported a mortality risk ratio of 0.59, but with I² of 84%, no effect on ventilation or length of stay, and an explicit call for randomised trials.

What does the TLR9 mechanism mean, and has a receptor been identified?

It means the peptide acts on innate pathogen-sensing machinery rather than directly on T cells: genetic studies in mice showed protection in fungal and cytomegalovirus infection required intact Toll-like receptor and MyD88 signalling. No high-affinity receptor has been identified in four decades. The current account describes a disordered peptide engaging multiple innate receptors with low individual affinity, which means conventional receptor pharmacology is unavailable here.

Is research-grade thymosin alpha-1 legal to buy?

Purchasing chemicals for legitimate laboratory research is generally lawful, subject to local controls. What is not lawful is marketing or supplying the compound for human consumption, or representing it as a treatment for any condition. Buyers are responsible for compliance with applicable law, institutional review and biosafety requirements in their own jurisdiction.

Why does endotoxin testing matter more for this peptide than for others?

Because the proposed mechanism and the classic endotoxin response overlap almost completely in their readouts. Tα1 is thought to act via TLR2 and TLR9; bacterial lipopolysaccharide acts via TLR4, and both produce dendritic cell maturation, cytokine induction and interferon responses. A contaminated preparation can reproduce the expected result through an entirely different pathway, which makes endotoxin quantification essential for credible in vitro immunology.

The Bottom Line

Thymosin alpha-1 is one of the few compounds in the research-peptide catalogue with a genuine, decades-long clinical development record, and that record is more informative for what it rules out than for what it establishes.

What is well supported: it is a defined 28-residue acetylated peptide derived from a real precursor protein, with a mechanism interrogated using genetic tools rather than inferred from correlation. TLR9- and TLR2-dependent dendritic cell activation, and the downstream Th1 polarisation and interferon responses, are among the better-characterised mechanisms attributed to any peptide in this market.

What is not supported: efficacy in sepsis which was tested properly and failed, TESTS was double-blinded, placebo-controlled, adequately powered at 1,106 participants, and null. Efficacy in COVID-19 which rests on observational data with severe heterogeneity that its own authors decline to call conclusive. The hepatitis indications which reflect an older evidence standard. And the immune reconstitution work which reports surrogate improvements more reliably than clinical ones.

For a laboratory the compound remains a legitimate, reasonably well-characterised tool for innate immune signalling research, with the caveat that endotoxin control is not optional. For anyone reading sourcing material, the two claims to reject immediately are that it is FDA approved, it is not, and never has been, and that it is a proven sepsis therapy, which a well-conducted 2025 trial specifically found it is not.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

Thymosin alpha-1, KPV, BPC-157 and all other compounds discussed in this article are intended for laboratory research use only. Thymosin alpha-1 is not approved by the U.S. Food and Drug Administration for the diagnosis, treatment, cure or prevention of any disease, in any species, and is not an approved dietary supplement ingredient in the United States. Orphan drug designation is not marketing approval, and marketing authorisation of thymalfasin products in other jurisdictions confers no status under FDA review.

Nothing in this article is medical, veterinary or pharmaceutical advice, and nothing in it constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Peptides described here are not for human or veterinary use. Concentrations and doses referred to from the literature are described only in the terms the original investigators reported for the specific model studied, and are not recommendations, conversions or equivalents for any other species or route. Descriptions of published clinical findings are summaries of what the cited literature reports, not endorsements or claims of efficacy. Readers with clinical questions should consult a qualified healthcare professional. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Stay updated, free articles. Join our Telegram channel

Join